Abstracts tagged "biologic response modifiers"

Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…
Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Avram Z. Goldberg¹, Thomas D. Geppert², Elena Schiopu³, Tracy M. Frech⁴, Vivien M. Hsu⁵, Robert W. Simms⁶, Stanford L. Peng⁷, Yihong Yao⁸, Nairouz Elgeioushi⁹, Bing Wang¹⁰, Linda Chang¹¹ and Stephen Yoo¹², ¹Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, ²Metroplex Clinical Research Center, LLC, Dallas, TX, ³Rheumatology/Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Department of Rheumatology, Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Medical Biostatistics, MedImmune, Gaithersburg, MD, ¹⁰Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ¹¹Translational Sciences, MedImmune, Hayward, CA, ¹²Clinical Development, MedImmune, Gaithersburg, MD
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…
Abstract Number: 1817 • 2012 ACR/ARHP Annual Meeting
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
Joseph R. Lutt¹ and Kevin L. Winthrop², ¹Colorado Center for Arthritis & Osteoporosis, Boulder, CO, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…
Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…
Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…
Abstract Number: 500 • 2012 ACR/ARHP Annual Meeting
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Yoshihiro Hishitani¹, Yoshihito Shima¹, Toru Hirano¹, Keisuke Hagihara², Kosuke Ebina³, Yasuo Kunugiza⁴, Kenrin Shi³, Masashi Narazaki¹, Atsushi Ogata¹, Tetsuya Tomita⁵, Toshio Tanaka¹ and Atsushi Kumanogoh¹, ¹Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, ²Department of Kampo Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁴Orthopedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Dept of Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibitors (TNF-Is) show inadequate response to TNF-Is. But it has not been clarified what is…
Abstract Number: 1684 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents
Signe Abitz Winther¹, Peter Riis Hansen¹, Søren Lund Kristensen¹, Lene Dreyer², Ole Ahlehoff¹, Louise Linde³, Christian Torp-Pedersen¹ and Jesper Lindhardsen¹, ¹Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease, but in contrast to the well-established risk of myocardial infarction (MI), the…
Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Jean-Pascal Roussy¹, Louis Bessette², Sasha Bernatsky³, Elham Rahme⁴ and Jean Lachaine¹, ¹Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…
Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Diane Lacaille¹, Michal Abrahamowicz², Eric C. Sayre³ and John Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…
Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Cesar Vargas-Serafin¹, Luis Aguilar-Lozano¹, Jorge Padilla-Ibarra¹, Carlos Sandoval-Castro¹, Jose Dionisio Castillo-Ortiz¹, Jorge Morales-Torres², Claudia Hernandez² and Cesar Ramos-Remus¹, ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Rheumatology, Hospital Aranda de la Parra, Leon, Mexico
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…
Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Michele Hooper¹, Deborah Wenkert², Bojena Bitman³, Virgil C. Dias⁴, Yessinia Bartley⁵, Julie Wang⁶ and Julia R. Gage⁷, ¹Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ²Inflammation TA, Amgen Inc., Thousand Oaks, CA, ³Amgen, Inc., San Francisco, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Assent Consulting, Solana Beach, CA, ⁶Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA, ⁷Gage Medical Writing, LLC, Oak Park, CA
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…
Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting
Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Chi Chiu Mok¹, Cherry Kwan¹, Helen Chan², Ka Lai Lee³ and Lai-Shan Tam⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rehabilitation, Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, ³Medicine, Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…
Abstract Number: 1569 • 2012 ACR/ARHP Annual Meeting
Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-2
Mie Fusama¹, Hideko Nakahara², Keisuke Kawamoto³, Satoko Nozato³, Midori Taguchi³, Kohji Nishioka³, Shinji Higa³, Eiji Takeuchi⁴, Kayoko Higashi⁵, Masao Yukioka⁶, Tsuyoshi Igarashi³, Taro Kuritani³, Keiji Maeda³ and Yasushi Miura⁷, ¹Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ³Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, NTT West Osaka Hospital, Osaka, Japan, ⁵Division of nursing, NTT West Osaka Hospital, Osaka, Japan, ⁶Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
Background/Purpose: Biologics significantly improve disease activity of rheumatoid arthritis (RA), however, patient global assessment (PGA) is not always improved in parallel with disease activity scores.…
Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Paul Emery¹, Piotr Wiland², Wolfgang Spieler³, Jean Dudler⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁵, Andrew S. Koenig⁵, Bonnie Vlahos⁵ and Sameer Kotak⁶, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Department of Rheumatology, University Hospital of Lausanne, Lausanne, Switzerland, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
Abstract Number: 1552 • 2012 ACR/ARHP Annual Meeting
Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the ‘Biologic Era’ : A Case-Control Study
Ashima Makol¹, Cynthia S. Crowson², Eric L. Matteson³ and Kenneth J. Warrington¹, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: 1.To determine the clinical presentation, treatment and outcomes of vasculitis (RV) associated with rheumatoid arthritis (RA) in the era of biologic use. 2. To…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].